Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine

Rafael Rosell, Laura Bonanno, Miquel Taron

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lung cancer driven by EGF receptor (EGFR)-sensitizing mutations is a new entity that requires a molecular diagnosis. Screening for EGFR mutations should be mandatory in lung cancer tumors for never-smokers regardless of histology, also in adenocarcinomas and large-cell carcinomas regardless of smoking history. EGFR mutations are more frequently found in women than men. Response to EGFR tyrosine kinase inhibitors in patients with EGFR mutations is very high with significant improvement in progression-free survival. However, the duration of progression-free survival is unpredictable at the individual level. Genetic modifiers, such as the BRCA1/NFKBIA mRNA expression could greatly predict the duration of response and pave the way for development of novel therapeutic interventions.

Original languageEnglish
Title of host publicationEGFR Inhibitors in Cancer Treatment
PublisherFuture Medicine Ltd.
Pages19-32
Number of pages14
ISBN (Print)9781780840260, 9781780841137
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Precision Medicine
Epidermal Growth Factor Receptor
Patient Selection
Mutation
Disease-Free Survival
Lung Neoplasms
Large Cell Carcinoma
Protein-Tyrosine Kinases
Histology
Adenocarcinoma
Smoking
History
Messenger RNA
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rosell, R., Bonanno, L., & Taron, M. (2012). Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine. In EGFR Inhibitors in Cancer Treatment (pp. 19-32). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.46

Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine. / Rosell, Rafael; Bonanno, Laura; Taron, Miquel.

EGFR Inhibitors in Cancer Treatment. Future Medicine Ltd., 2012. p. 19-32.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rosell, R, Bonanno, L & Taron, M 2012, Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine. in EGFR Inhibitors in Cancer Treatment. Future Medicine Ltd., pp. 19-32. https://doi.org/10.2217/EBO.11.46
Rosell R, Bonanno L, Taron M. Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine. In EGFR Inhibitors in Cancer Treatment. Future Medicine Ltd. 2012. p. 19-32 https://doi.org/10.2217/EBO.11.46
Rosell, Rafael ; Bonanno, Laura ; Taron, Miquel. / Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine. EGFR Inhibitors in Cancer Treatment. Future Medicine Ltd., 2012. pp. 19-32
@inbook{c117645b0c544646a02e58da4c55a01d,
title = "Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine",
abstract = "Lung cancer driven by EGF receptor (EGFR)-sensitizing mutations is a new entity that requires a molecular diagnosis. Screening for EGFR mutations should be mandatory in lung cancer tumors for never-smokers regardless of histology, also in adenocarcinomas and large-cell carcinomas regardless of smoking history. EGFR mutations are more frequently found in women than men. Response to EGFR tyrosine kinase inhibitors in patients with EGFR mutations is very high with significant improvement in progression-free survival. However, the duration of progression-free survival is unpredictable at the individual level. Genetic modifiers, such as the BRCA1/NFKBIA mRNA expression could greatly predict the duration of response and pave the way for development of novel therapeutic interventions.",
author = "Rafael Rosell and Laura Bonanno and Miquel Taron",
year = "2012",
month = "1",
day = "1",
doi = "10.2217/EBO.11.46",
language = "English",
isbn = "9781780840260",
pages = "19--32",
booktitle = "EGFR Inhibitors in Cancer Treatment",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine

AU - Rosell, Rafael

AU - Bonanno, Laura

AU - Taron, Miquel

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Lung cancer driven by EGF receptor (EGFR)-sensitizing mutations is a new entity that requires a molecular diagnosis. Screening for EGFR mutations should be mandatory in lung cancer tumors for never-smokers regardless of histology, also in adenocarcinomas and large-cell carcinomas regardless of smoking history. EGFR mutations are more frequently found in women than men. Response to EGFR tyrosine kinase inhibitors in patients with EGFR mutations is very high with significant improvement in progression-free survival. However, the duration of progression-free survival is unpredictable at the individual level. Genetic modifiers, such as the BRCA1/NFKBIA mRNA expression could greatly predict the duration of response and pave the way for development of novel therapeutic interventions.

AB - Lung cancer driven by EGF receptor (EGFR)-sensitizing mutations is a new entity that requires a molecular diagnosis. Screening for EGFR mutations should be mandatory in lung cancer tumors for never-smokers regardless of histology, also in adenocarcinomas and large-cell carcinomas regardless of smoking history. EGFR mutations are more frequently found in women than men. Response to EGFR tyrosine kinase inhibitors in patients with EGFR mutations is very high with significant improvement in progression-free survival. However, the duration of progression-free survival is unpredictable at the individual level. Genetic modifiers, such as the BRCA1/NFKBIA mRNA expression could greatly predict the duration of response and pave the way for development of novel therapeutic interventions.

UR - http://www.scopus.com/inward/record.url?scp=84956832946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956832946&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.46

DO - 10.2217/EBO.11.46

M3 - Chapter

AN - SCOPUS:84956832946

SN - 9781780840260

SN - 9781780841137

SP - 19

EP - 32

BT - EGFR Inhibitors in Cancer Treatment

PB - Future Medicine Ltd.

ER -